Also known as: PNB-0408
An angiotensin IV analog marketed as a powerful memory enhancer.
Educational reference, not medical advice. Many compounds here are not approved, and products sold as research chemicals are not checked for purity. Plan any use with a licensed clinician.
How it works
Strengthens HGF/c-Met signaling, which helps neurons form new connections in rat studies.
Evidence by goal
| Goal | Grade | What the grade means |
|---|---|---|
| Focus, memory & brain | D | Animal or cell studies only |
At a glance
- Route
- Oral or transdermal
- Half-life
- Long (days)
Reported dosing
10 to 20 mg daily (user reports only).
Timing: Morning.
Cycle: Short courses; long-term safety unknown.
From approved labels where they exist, otherwise from published trials and practitioner reports.
Side effects
- Unknown in humans
Who should avoid it
- Any cancer history (c-Met is a cancer-growth pathway)
Often combined with
None established.
Key findings
Only animal data. A related drug from the same research line (fosgonimeton) failed its Alzheimer's trial in 2024.
Where it is legal (Oct 2026)
| US | Not approved |
|---|---|
| Canada | Not approved |
| Mexico | Not approved |
| EU | Not approved |
Sources
Open Dihexa in the Peptide Guide Compare all peptides by goal
Last reviewed November 2026. Regulatory status reflects the US unless noted and changes often.